Govert J. Schouten
Direttore/Membro del Consiglio presso Cristal Delivery BV
Profilo
Govert J.
Schouten was the founder of Impatients NV, which was founded in 2012, where he held the title of Chief Business Officer.
He is currently a Member-Supervisory Board at Cristal Delivery BV.
In the past, he worked as the Chief Executive Officer at Mucosis BV from 2008 to 2012, Vice President-Business Development at Crucell NV, and Head-Innovation at Kiadis Pharma NV.
Dr. Schouten received his graduate and doctorate degrees from the University of Leiden.
Posizioni attive di Govert J. Schouten
| Società | Posizione | Inizio |
|---|---|---|
Cristal Delivery BV
 Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Govert J. Schouten
| Società | Posizione | Fine |
|---|---|---|
Mucosis BV
 Mucosis BV Miscellaneous Commercial ServicesCommercial Services Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands. | Presidente | 20/09/2012 |
| KIADIS PHARMA N.V. | Corporate Officer/Principal | - |
Impatients NV
 Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Fondatore | - |
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Corporate Officer/Principal | - |
Formazione di Govert J. Schouten
| University of Leiden | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Mucosis BV
Mucosis BV Miscellaneous Commercial ServicesCommercial Services Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands. | Commercial Services |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Commercial Services |
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Cristal Delivery BV
Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Govert J. Schouten
